INCY News and Press, Incyte Corporation From 04/15/20

The FDA has signed off on Fast Track status for Yantai, China-based RemeGen 's lead drug RC18 for the treatment of systemic lupus erythematosus (SLE). More news on: GlaxoSmithKline plc, Mallinckrodt plc, Biogen Inc., Healthcare stocks news, Read more ...

Galidesivir, not berotralstat, will be the BCRX catalyst Oral berotralstat is soon likely to gain approval in three regions - Japan, the U.S., and Europe - for the treatment of HAE. In Japan, a new drug application for berotralstat is currently being reviewed by the Pharmaceuticals and Med...

April 14, 2020 Palm Beach, FL – April 14, 2020 – Many According to the World Health Organization (WHO) there are 70 coronavirus vaccines in development globally, with three candidates already being tested in human trials, as drugmakers race to find a cure for the dea...

We're now going through the hard part of the stock-market crash. The relentless downward momentum has eased, and we've even seen some rallies, not to mention indications that the coronavirus curve is in fact leveling (e.g., the New York City epicenter ). But bear market rallies are real ...

Help is on the way. In the midst of a societal upheaval resulting from the novel coronavirus and the disease that it causes, COVID-19, there are many efforts in progress to find solutions to slow the spread of the disease and treat those who already have it. These efforts include those from gov...

GlaxoSmithKline's Nucala Achieves Co-Primary Endpoints GlaxoSmithKline ( GSK ) announced that its drug candidate Nucala met co-primary endpoints for the pivotal SYNAPSE study. The trial was designed to assess the efficacy of this asthma drug in treating patients with nasal polyps associa...

Following up on its initial announcements in January and February , Incyte (NASDAQ: INCY ) reports detailed results from two successful Phase 3 clinical trials, TRuE-AD1 and TRuE-AD2 , evaluating a topical cream formulation of kinase inhibitor ruxolitinib in adolescents and adults wi...

- Ruxolitinib cream resulted in a rapid and robust clinical response, with significantly more patients achieving Investigator’s Global Assessment (IGA) Treatment Success (IGA-TS; primary endpoint), defined as an IGA score of 0 (clear) or 1 (almost clear), and EASI75 (key secondary en...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Cancer and a viral infections wouldn't seem to have much in common, but Incyte (NASDAQ: INCY) is testing its blood cancer drug Jakafi in patients with COVID-19 , the disease caused by the new coronavirus. The connection is that Jakafi helps patients with a blood cancers by inhibiting immun...